Navigation Links
Anti-spasticity medications need further research

Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review of scientific literature headed by a UT Southwestern Medical Center neurologist and conducted by a national panel of interdisciplinary experts nationwide.

The findings prompted the American Academy of Neurology to release a new practice guideline on effective treatments. Dr. Mauricio Delgado-Ayala, professor of neurology at UT Southwestern is lead author of the guideline, which appears in the Jan. 26 issue of the academy's journal, Neurology.

Botulinum toxin type A, sold under the brand names Botox and Dysport, is effective and generally safe to relieve spasticity, the researchers found. The drugs diazepam (Valium) and tizanidine (Zanaflex, Sirdalud) can also be used, although they carry more risks.

The researchers found insufficient evidence on whether other commonly used drugs are effective or safe.

A statement by the academy said that practice guidelines are intended to keep neurologists up to date on clinical research and improve medical treatment; they are not intended as hard-and-fast rules.

"The guideline identified a need for more research on most drugs used to treat generalized spasticity," said Dr. Delgado-Ayala. "These drugs might work and be safe, but that needs to be proved.

The lack of evidence does not mean that existing treatment methods are not effective and safe, but it should make us pause and realize that more research needs to be conducted."Most of the medications we use in children were originally studied in adults," Dr. Delgado-Ayala said. "We need to know more about how these medications work in the body, and the doses for best results and least side effects, not only to reduce spasticity but also to improve quality of life."

About 10,000 babies a year in the U.S. are born with cerebral palsy. Cerebral palsy comprises several types of movement disorders, sometimes accompanied by learning disorders, epilepsy and other conditions. The most common characteristic is spasticity, in which muscles tense and flex uncontrollably.

Botox and other drugs can be legally prescribed to treat spasticity, but this use is considered "off-label" because they have not been specifically approved by the Food and Drug Administration for that condition.

For the practice guideline panel, the American Academy of Neurology enlisted five pediatric neurologists, two developmental pediatricians, one pediatric physiatrist, one pediatric orthopedist and one adult neurologist. The panelists examined 218 research studies, all of which appeared in peer-reviewed journals and involved cerebral palsy patients under the age of 19, with at least nine patients studied. The panel made recommendations according to the level of evidence found.

Overall, the literature review identified a large "research gap," showing that the effectiveness, mechanism and safety of many drugs has not been adequately studied in children, Dr. Delgado-Ayala said.

"There is an urgent need to develop new drugs to treat spasticity in general," he said. "There has not been a new drug approved for spasticity by the FDA in more than 10 years."


Contact: Aline McKenzie
UT Southwestern Medical Center

Related medicine news :

1. A novel computational model -- how Parkinsons medications affect learning and attention
2. First Oral Medications For MS Show Promise
3. Monitoring of high-risk medications unchanged despite FDA warnings
4. Urinary Incontinence Rates Increase Worldwide As Awareness Grows About Treatment Options: Urethral Slings Are Popular Alternatives When Medications Fail
5. Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction
6. Study highlights lack of patient knowledge regarding hospital medications
7. Launches My Health Tracker, Enabling HIV-Positive Patients to Track Lab Results, Medications and Supplements
8. Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery
9. Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs
10. Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS
11. Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents, According to Scientists at the Feinstein Institute for Medical Research and Zucker Hillside Hospital
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: